The dual-targeted IONPs efficiently bond to both LRP5/6 and uPAR, resulting in inhibition of the Wnt/β-catenin signaling and the CSC-like phenotype of cancer cells as validated by a noticeable reduction in the expressions of LRP5/6, CD44, and uPAR. This evidence concerns the gene LRP5 and cancer.